Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 90 Next >>

Filter Applied: MRI,abnormal (Click to remove)

Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024

Progressive Hemiparesis and White Matter Abnormalities in an HIV-Negative Patient
Neurol 100:1156-1163, Jabbari,E.,et al, 2023

Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment
Neurol 101:1079-1080, Bonami,S.,et al, 2023

Confused About Confusion
NEJM 386:80-87, Spanjaart, A.M.,et al, 2022

Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
JENDSO 6:1-7, Hamidi, S.,et al, 2022

Atypical Posterior Reversible Encephalopathy Syndrome Associated with Lenvatinib Therapy in a Patient with Metastatic Thyroid-Cancer
Cancer Reports doi:10.1002/cnr2.1605, Abhishek, M.,et al, 2022

A 48-Year-Old Woman with 6 Months of Vivid Visual Hallucinations
Neurol 99:166-171, Kizza, J.,et al, 2022

Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022

Clinicopathologic Conference, Encephalitis due to Behcets Disease
NEJM 387:925-933, Case 27-2022, 2022

Pembrolizumab-Induced Migrating Cortico-Subcortical Brain Lesions
Ann Neurol 89:1255-1256, Lambert, N.,et al, 2021

Cerebral Venous Thrombosis
NEJM 385:59-64, Ropper, A.H. & Kline, J.P., 2021

Encephalitis Induced by Immune Checkpoint Inhibitors
JAMA Neurol 78:864-873, Velasco, R.,et al, 2021

Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021

Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020

"CHOICES": An Acronym to Aid in Delineating Potential Causes of Non-Metabolic, Non-Infectious Acute Toxic Leukoencephalopathy
EJR OPEN 6:243-257, Koksel, Y.,et al, 2019

Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018

Headache and Altered Mental Status
Neurol 90:e1267-e1270, Spera, K.M.,et al, 2018

Autoimmune Pancerebellitis Associated with Pembrolizumab Therapy
Neurol 91:91-93, Vitt, J.R.,et al, 2018

Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018

Progressive Multifocal Leukoencephalopathy: Epidemiology, Clinical Manifestations, and Diagnosis
www.UptoDate.com, May, Koralnik, I.J., 2018

Nivolumab-Induced Autoimmune Encephalitis in Two Patients with Lung Adenocarcinoma
Case Rep Neurol Med 2018;doi:10.1155/2018/2548528, Shah, S.,et al, 2018

Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017

Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017

Infliximab for the Treatment of CNS Sarcoidosis
Neurol 89:2092-2100, Gelfand, J.M.,et al, 2017

Should Patients with Ischemic Stroke or Transient Ischemic Attack with Atrial Fibrillation and Microbleeds be Anticoagulated?
Stroke 48:3408-3412, Shoamanesh, A.,et al, 2017

Clinicopathologic Conference, Paroxysmal Nocturnal Hemoglobinuria
NEJM 377:2581-2590, Case 40-2017, 2017

Embolic Stroke, Atrial Fibrillation, and Microbleeds
Stroke 47:904-907, Diener, H-C.,et al, 2016

Clinicopathologic Conference, Neurosarcoidosis
NEJM 374:1966-1975, Case 15-2016, 2016

Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015

Safety and Efficacy of Ofatumumab in Relapsing-Remitting Multiple Sclerosis
Neurol 82:573-581, Sorensen, P.S.,et al, 2014

Treatment of Primary CNS Vasculitis with Rituximab: Case Report
Neurol 82:1287-1288, Salvarani, C.,et al, 2014

Effect of Rituximab in Patients with Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy
JAMA Neurol 71:896-900, Irani, S.R.,et al, 2014

Infections of the Nervous System, (Bacterial, Fungal, Spirochetal, Parasitic) and Sarcoidosis, Sarcoidosis
Adams & Victors Principles of Neurology, Chp 32, pg 721, Ropper, A.H.,et al, 2014

Varicella-Zoster Virus Acute Myelitis in a Patient with MS Treated with Natalizumab
Neurol 80:1812-1813, Yeung, J.,et al, 2013

Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013

Sarcoidosis Presenting as Longitudinally Extensive Myelitis
Neurol 81:e61, Goenka, N. & Venna N., 2013

Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013

Natalizumab-Associated PML Identified in the Presymptomatic Phase Using MRI Surveillance
Neurol 78:507-508, Blair,N.F.,et al, 2012

Update on the Pathophysiology and Management of Idiopathic Intracranial Hypertension
JNNP 83:488-494, Biousse,V.,et al, 2012

PML-IRIS in a patient treated with Brentuximab
Neurol 79:2075-2077, Geldern, G.,et al, 2012

Fatal Varicella-Zoster Virus Vasculopathy Associated with Adalimumab Therapy
Arch Neurol 69:1193-1196, Baek, W.,et al, 2012

Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas are Associated with Improved Survival Compared with Matched Controls
AJNR 33:1763-1770, Mong, S.,et al, 2012

Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Arch Neurol 68:186-191, Miravalle,A.,et al, 2011

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011

Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis
Arch Neurol 68:1156-1164, Clifford, D.B.,et al, 2011

Clinicopathologic Conference, Limbic Encephaitis with Antibodies to Leucine - Rich Glioma - inactivated 1 (LGI 1).
NEJM 365:1825-1833, Case 34-2011, 2011

Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011



Showing articles 0 to 50 of 90 Next >>